journal cover

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Aug 7, 2009

Nassim KamarLionel Rostaing

Download from

Publisher
PubMed

Abstract

Rituximab off-label use includes organ transplantation. We review the occurrence of infectious disease and its outcome after rituximab therapy. Between April 2004 and August 2008, 77 kidney-transplant patients received rituximab therapy [2-8 courses (median 4) of 375 mg/m2 each] for var...read more

Mentioned in this Paper

Monoclonal Antibodies
Mycoses
Virus Diseases
Globulins
Nested Case-Control Studies
Safety
Eye Infections, Viral
Lung Diseases, Fungal
Globulin Measurement
Mabthera
28
1
Paper Details
References
  • References37
  • Citations82
1234
  • References37
  • Citations82
12345...

Feeds With Similar Papers

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Related Papers

© 2020 Meta ULC. All rights reserved

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Aug 7, 2009

Nassim KamarLionel Rostaing

PMID: 19656128

DOI: 10.1111/j.1600-6143.2009.02785.x

Abstract

Rituximab off-label use includes organ transplantation. We review the occurrence of infectious disease and its outcome after rituximab therapy. Between April 2004 and August 2008, 77 kidney-transplant patients received rituximab therapy [2-8 courses (median 4) of 375 mg/m2 each] for var...read more

Mentioned in this Paper

Monoclonal Antibodies
Mycoses
Virus Diseases
Globulins
Nested Case-Control Studies
Safety
Eye Infections, Viral
Lung Diseases, Fungal
Globulin Measurement
Mabthera
28
1

Feeds With Similar Papers

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Related Papers

Transplant Infectious Disease : an Official Journal of the Transplantation Society

Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient

Transplant Infectious Disease : an Official Journal of the Transplantation SocietySeptember 23, 2008
D KumarA Humar
Paper Details
References
  • References37
  • Citations82
1234
  • References37
  • Citations82
12345...

Download from

Publisher
PubMed
/papers/incidence-and-predictive-factors-for-infectious/19656128